Shots: The 2 P-III ILLUMINATE SWITCH A & B trials evaluate doravirine/islatravir (100/0.75mg, qd, PO) in a ratio (1:1) in 672 & 641 patients with HIV-1 who are virologically suppressed […]readmore
Tags : Fixed Dose Combination
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Boehringer Ingelheim
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Lilly
Merck
Novartis
P-III
patients
Pfizer
receives
Regeneron
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
Treat
Treatment
US